Kuzmenko A V, Gyaurgiev T A, Kuzmenko G A
Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia.
Urologiia. 2022 May(2):84-89.
Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are among the most common causes of LUTS in men. LUTS occur on average in 62.5% of males, with irritative symptoms occurring in 51%, obstructive symptoms in 26%, and postmicturic symptoms in 17% of cases. According to the literature, moderate and severe LUTS were observed in 13% of men under the age of 50 and in 28% after 70 years. It should be noted that LUTS are not BPH-specific, since may be caused by prostate inflammation. According to publications, 57% of patients examined for CP have BPH, and 39% of patients with BPH have CP. The first line of drug therapy in patients with BPH is currently considered to be alpha-blockers and inhibitors of 5-a-reductase. In addition, it is possible to use herbal preparations made from fruits, roots, seeds, pollen and plant bark. Preparations based on Serenoa repens extract are among the most studied and are widely used both in our country and worldwide for the treatment of patients with BPH and LUTS. Only lipidosterol hexane extract of Serenoa repens is recognized as a drug, the use of which has a good evidence base. The clinical examples illustrating the pharmacological properties and results of the use of the preparation of lipidosterol hexane extract Serenoa repens are presented in the article. CONCLUSION: The presented clinical cases demonstrate the efficiency of the hexane extract of Serenoa repens fruit for the treatment of LUTS associated with BPH and CP. At the same time, the drug can be effectively used both as monotherapy and in combination with alphablockers. Therefore, it is reasonable to use the hexane extract of Serenoa repens fruit in clinical practice for the treatment of LUTS associated with BPH.
良性前列腺增生（BPH）和慢性前列腺炎（CP）是男性下尿路症状（LUTS）最常见的病因。LUTS平均发生在62.5%的男性中，其中刺激性症状占51%，梗阻性症状占26%，排尿后症状占17%。根据文献，50岁以下男性中13%出现中度和重度LUTS，70岁以后这一比例为28%。应当指出，LUTS并非BPH所特有，因为它可能由前列腺炎症引起。根据出版物，接受CP检查的患者中有57%患有BPH，而患有BPH的患者中有39%患有CP。目前，BPH患者药物治疗的一线药物被认为是α受体阻滞剂和5-α还原酶抑制剂。此外，也可以使用由水果、根、种子、花粉和植物树皮制成的草药制剂。基于锯叶棕提取物的制剂是研究最多的，在我国和全世界都广泛用于治疗BPH和LUTS患者。只有锯叶棕脂质甾醇己烷提取物被认可为一种药物，其使用有充分的证据基础。本文介绍了说明锯叶棕脂质甾醇己烷提取物制剂药理特性和使用结果的临床实例。结论：所呈现的临床病例证明了锯叶棕果实己烷提取物治疗与BPH和CP相关的LUTS的有效性。同时，该药物既可以作为单一疗法有效使用，也可以与α受体阻滞剂联合使用。因此，在临床实践中使用锯叶棕果实己烷提取物治疗与BPH相关的LUTS是合理的。
